Revised: March 2, 2011
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
People are exposed to different strains of the influenza virus many times during their lives. Even though the virus changes over time, previous bouts of influenza may offer some protection against infection caused by a similar strain of the virus.
However, three to four times each century, for unknown reasons, a radical change takes place in the influenza A virus causing a new strain to emerge. Since people have no protection against the new strain, it can spread rapidly around the world, causing what is known as a pandemic. The pandemic influenza virus may cause severe complications, such as pneumonia and death in previously healthy individuals.
For more information about pandemic influenza consult the Public Health Agency of Canada Web site at www.fightflu.ca.
Antiviral drugs, such as oseltamivir (Tamiflu«), zanamivir (Relenza«) and amantadine, are used for the prevention and early treatment of influenza, and are expected to be widely used if there is an influenza pandemic, particularly since a pandemic influenza vaccine is unlikely to be available in the early months of a pandemic.
Antiviral drugs, when taken early in the illness (within 48 hours) can reduce influenza symptoms, shorten the length of illness and potentially reduce the serious complications of influenza. As well, antiviral drugs may prevent influenza infection if they are taken during periods of potential exposure to the virus. Antiviral drugs can come in pill, syrup/liquid, or inhaler form.
Vaccines are the primary means to prevent illness from influenza. They stimulate the production of antibodies against the flu virus, providing immunity against the virus. At the start of an influenza pandemic, it may take several months before a new vaccine can be developed. Antiviral drugs are not a vaccine.
Antiviral drugs are assessed by Health Canada for safety, effectiveness and quality before they can be sold in Canada. Once approved, they are assigned an eight-digit Drug Identification Number (DIN).
Health Canada continues to monitor the safety profile of the health products sold in Canada, to ensure that the benefits of using a product continue to outweigh the risks that may be associated with its use. Some of these risks are known at the time the drug is approved, but additional information about risks can only become known once the product is more widely used.
At this point in time, serious adverse reactions to antiviral drugs have been very rare. However, during a pandemic is essential to look for and respond to any serious adverse reactions that may occur with widespread use of these drugs, as this information will help guide the safest and most effective use of these drugs.
During an influenza pandemic, Health Canada will make the assessment of suspected adverse reactions to antiviral medications a priority, to ensure that any new safety concerns are identified and communicated quickly to help inform the appropriate use of these products.
All serious suspected adverse reactions should be reported. A serious adverse reaction is one that:
To assist in the assessment of the adverse reaction reports as much information as possible should be provided in the report. Please include the following details when possible:
Although every adverse reaction report is important, reporting all suspected adverse reactions may not be feasible due to the impact of the influenza pandemic on the health care system and the daily lives of Canadians in general. The most important information to report will be those most serious adverse reactions that may impact on the decision to use one or more of the antiviral drugs for the prevention or treatment of influenza.
Health professionals and the general public are encouraged to use one of the following three methods to report an adverse reaction to Health Canada:
Health Canada's Canada Vigilance Program is responsible for the collection and assessment of adverse reaction reports that have been submitted by health professionals and consumers; the first phase of the post market surveillance continuum. Information from domestic adverse reaction reports is essential to monitoring the safety of health products. Adverse reaction reporting helps identify, assess and inform Canadians of new health product safety issues. Having access to the latest safety information helps Canadians make informed decisions about the use of drugs and health products.
The Canada Vigilance Adverse Reaction Online Database can be used to retrieve essential information from adverse reaction reports. It is available at www.health.gc.ca/medeffect and is intended solely to provide health product information as reported to Health Canada. It cannot be used on its own to evaluate a health product's safety profile and does not provide conclusive information on the safety of health products.
Additional information for health professionals and consumers regarding adverse reaction reporting may be found in the guidance document Guidelines - Voluntary Reporting of Suspected Adverse Reactions to Health Products by Health Professionals and Consumers, located on the MedEffect Canada™ section of the Health Canada Web site at: www.health.gc.ca/medeffect
For more information on the Canada Vigilance Program, health professionals and consumers may contact the appropriate Canada Vigilance Regional Office listed below. The following toll-free numbers may also be used. Calls will be automatically routed to the appropriate Canada Vigilance Regional Office based on the area code from which the call originates.
Telephone (toll-free): 1-866-234-2345
Fax (toll-free): 1-866-678-6789
British Columbia and Yukon
Canada Vigilance Regional Office - British Columbia and Yukon
400 - 4595 Canada Way,
Burnaby, British Columbia V5G 1J9
Alberta and Northwest Territories
Canada Vigilance Regional Office - Alberta and Northwest Territories
Suite 730, 9700 Jasper Avenue
Edmonton, Alberta T5J 4C3
Canada Vigilance Regional Office - Saskatchewan
4th floor, Room 412
101 - 22nd Street East
Saskatoon, Saskatchewan S7K 0E1
Canada Vigilance Regional Office - Manitoba
510 LagimodiŔre Blvd
Winnipeg, Manitoba R2J 3Y1
Ontario and Nunavut
Canada Vigilance Regional Office - Ontario and Nunavut
2301 Midland Avenue
Toronto, Ontario M1P 4R7
Canada Vigilance Regional Office - Quebec
Suite 202-40, 2nd Floor, East Tower
200 René-Lévesque Boulevard West
Montréal Québec H2Z 1X4
New Brunswick, Nova Scotia, Prince Edward Island and, Newfoundland and Labrador
Canada Vigilance Regional Office - Atlantic
1505 Barrington St., Maritime Centre
Suite 1625, 16th floor
Halifax, Nova Scotia B3J 3Y6